HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[CD5-negative B-cell chronic lymphocytic leukemia (B-CLL) associated with massive splenomegaly and without lymphadenopathy].

Abstract
A 39-year-old male was referred to our hospital in June, 1993, because of leukocytosis. Physical examinations showed massive splenomegaly without any lymphadenopathy. The white blood cell count was 13,800/microliters with 87% morphologically mature lymphocytes. Bone marrow aspirate revealed hypercellularity with 67% lymphocytes morphologically similar to peripheral lymphocytes. The lymphocytes displayed monoclonal rearrangements of immunoglobulin genes and the phenotype of CD5-CD19+CD20+ CD21+ and Smlg+. Splenectomy was effective against neutropenia and thromboytopenia. The clinical and laboratory findings of this case were unusual compared to those of typical B-CLL in massive splenomegaly, no lymphadenopathy and CD5-phenotype, suggesting the heterogeneity of B-CLL.
AuthorsT Yamada, H Ninomiya, T Horiuchi, K Takada, T Hato, K Yamauchi, M Yasukawa, S Fujita
Journal[Rinsho ketsueki] The Japanese journal of clinical hematology (Rinsho Ketsueki) Vol. 36 Issue 10 Pg. 1230-2 (Oct 1995) ISSN: 0485-1439 [Print] Japan
PMID8531336 (Publication Type: Case Reports, Journal Article)
Chemical References
  • CD5 Antigens
  • Immunoglobulins
Topics
  • Adult
  • CD5 Antigens (immunology)
  • Gene Rearrangement
  • Humans
  • Immunoglobulins (genetics)
  • Leukemia, Lymphocytic, Chronic, B-Cell (complications, genetics, immunology)
  • Lymphatic Diseases
  • Male
  • Splenomegaly (complications, surgery)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: